Clinical Research Directory
Browse clinical research sites, groups, and studies.
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Sponsor: Josephine Connolly-Schoonen
Summary
This study will examine if a short-term, reduced protein diet for the 3-day period prior to and on the day of each of the first 4 chemotherapy cycles and 4 days prior to primary breast surgery is well tolerated and adhered to by patients with stage II or III estrogen receptor positive (ER+) human epidermal growth factor receptor negative (HER2-) breast cancer (BC) receiving neoadjuvant chemotherapy (NAC).
Official title: A Pilot Trial of Controlled Feeding With Reduced Dietary Protein in Patients With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2026-11-02
Completion Date
2029-04-30
Last Updated
2026-10-27
Healthy Volunteers
No
Interventions
Dietary Protein Intervention
Consume an intermittent, reduced protein diet for a total of 20 feeding days over the course of neoadjuvant treatment (at the time of the first four chemotherapy cycles and prior to surgery)
Locations (1)
Stony Brook Cancer Center
Stony Brook, New York, United States